Cargando…
Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma
SIMPLE SUMMARY: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphoma that remains incurable with standard therapy. A promising approach to overcome the low life expectancy of patients with MCL is drug repurposing, a strategy focused on finding novel therapeutic weapons...
Autores principales: | Santos, Juliana Carvalho, Profitós-Pelejà, Núria, Ribeiro, Marcelo Lima, Roué, Gaël |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688202/ https://www.ncbi.nlm.nih.gov/pubmed/36428695 http://dx.doi.org/10.3390/cancers14225601 |
Ejemplares similares
-
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
por: Profitós-Pelejà, Núria, et al.
Publicado: (2022) -
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021) -
RHOA Therapeutic Targeting in Hematological Cancers
por: Santos, Juliana Carvalho, et al.
Publicado: (2023) -
Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2021) -
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2023)